This Guide is part of WHO’s overall programme of work on Political Economy of Health Financing Reform: Analysis and Strategy to Support UHC. The impetus for this work came from demands for more concrete evidence, recognition and integration of political economy issues within
health financing, and... overall system, reform design and implementation processes. This Guide is complementary to WHO’s Health Financing Progress Matrix assessment, as well as Health Financing Strategy development guidance. In this way, it promotes an embedded political
economy analysis approach that can be used in conjunction with other health financing assessments and guidance. The political economy framework can also be extended and easily adapted to broader health policy reforms.
more
Questions concerning the relevance and reform of official development assistance (ODA), and how ODA and broader development finance could—or should—change to better reflect shifting demands are not new, with academics and policymakers suggesting a range of options for reform. In this background ...note, we briefly review the major reform proposals from 2009 onwards, highlighting the key issues underlying approaches to ODA reforms, and the main “types” of proposals typically put forward.
more
Frequent efforts to revise the official development assistance (ODA) accounting rules have raised important questions about the integrity and relevance of what currently “counts” as ODA spending. In this note, we outline a brief history of the evolution of the ODA accounting rules to date, highl...ighting how—and why—the ODA concept has changed since it emerged in 1969. Doing so provides a starting point for considering whether the current concept of ODA remains “fit for purpose” and whether, or how, the concept could reform to better meet current needs.
more
The UK could regain its leadershipin the provision of development assistance for healthunder the next government. But this doesn’t seem likely if the party manifestos are any guide.
The world is facing a sustainable development crisis. The 2024 Financing for Sustainable Development Report: Financing for Development at a Crossroads finds that financing challenges are at the heart of the crisis and imperil the SDGs and climate action. The window to rescue the SDGs and prevent a c...limate catastrophe is still open but closing rapidly. Financing gaps for sustainable development are large and growing – the estimates by international organizations and others are coalescing around $4 trillion additional investment needed annually for developing countries. This represents a more than 50% increase over the pre-pandemic estimates. Meanwhile, the finance divide has not been bridged, with developing countries paying around twice as much on average in interest on their total sovereign debt stock as developed countries. Many countries lack access to affordable finance or are in debt distress. Weak enabling environments are preventing progress. Average global growth has declined, while policy and regulatory frameworks still do not set appropriate incentives. Public budgets and spending is not fully aligned with SDGs. Private investors are not incentivised to invest enough in SDGs and climate action. The world is at a crossroads. This is the last chance to correct course if we want to achieve the SDGs by the 2030 deadline. Only an urgent, large-scale and sustainable investment push can help us achieve our global goals. Next year’s Fourth International Conference on Financing for Development in 2025 will be a once in 80-year opportunity to support coherent transformation of financing.
more
Todos los países de la Región de las Américas en los que la malaria es endémica han asumido el reto de eliminar la enfermedad y de poner en marcha medidas para orientar sus programas y estrategias de salud en esa dirección. En este manual se explica cómo ejecutar las medidas con vistas a logra...r la eliminación de la malaria y prevenir su restablecimiento, mediante el aumento de la intensidad y la calidad de las medidas, la reorientación de las iniciativas, la reducción de los retrasos que favorecen la transmisión y un monitoreo adecuado que permita ajustar las intervenciones. En este sentido, se propone como primer paso estratificar el territorio —de modo que se puedan planificar y priorizar las intervenciones y grupos de población— para, a continuación, aplicar una medida de diagnóstico, tratamiento, investigación y respuesta como estrategia clave dirigida a hacer efectiva la eliminación de la enfermedad y a prevenir su restablecimiento en todos los estratos. Además, el documento trata de hacer operativo el concepto de vigilancia, como intervención promovida por la Organización Mundial de la Salud a través de la Estrategia Técnica Mundial contra la Malaria 2016-2030, y destaca la importancia de que las comunidades tengan acceso al diagnóstico y el tratamiento tempranos. Por último, en el manual también se incluyen aspectos de gestión y monitoreo que deben tenerse en cuenta para la eliminación de los focos de transmisión.
more
Le flyer „MMV Strategy“ présente la stratégie de la Medicines for Malaria Venture (MMV) pour lutter contre le paludisme. Il met en avant les objectifs clés de l'organisation, qui se concentre sur la recherche et le développement de nouveaux médicaments antipaludiques. Le document décrit le...s efforts pour améliorer l'accès aux traitements de qualité, soutenir les partenariats mondiaux, et accélérer l'innovation dans la lutte contre le paludisme, avec un accent particulier sur les populations à risque élevé.
more
Le plan stratégique de la RBM Partnership to End Malaria pour 2021-2025 présente les priorités stratégiques du partenariat mondial visant à éliminer le paludisme. Le document se concentre sur trois objectifs stratégiques principaux : optimiser les programmes régionaux et nationaux, maximiser... le financement et faciliter le déploiement de nouveaux produits et stratégies. Le plan met l'accent sur la collaboration multisectorielle, en exploitant les partenariats au niveau mondial, régional et national pour lutter efficacement contre le paludisme. Il souligne également l'importance du partage de données, du plaidoyer et de la communication pour garantir que le paludisme reste une priorité en matière de santé. Le document met aussi en lumière les défis posés par la pandémie de COVID-19 et la nécessité de maintenir l'élan dans la lutte contre le paludisme.
more
Dieses Dokument stellt aktuelle Ergebnisse zum Thema Official Development Assistance (ODA) mit Fokus auf Gesundheit und Deutschland zur Verfügung.
Chapitre 50. Le texte traite du paludisme grave, une forme sévère du paludisme principalement causée par Plasmodium falciparum. Il explique les circonstances dans lesquelles le diagnostic doit être évoqué, notamment en cas de fièvre au retour d'une zone tropicale. Le document décrit les exam...ens nécessaires, les signes cliniques et biologiques de gravité, et insiste sur l’urgence du traitement. Le traitement de référence est l’artésunate par voie intraveineuse, suivi d’une thérapie orale. Le texte aborde aussi les complications possibles, les critères d’hospitalisation et l’importance d’une prise en charge rapide et adaptée dans un service spécialisé.
more
The webpage from Medicines for Malaria Venture (MMV) focuses on efforts to develop and provide child-friendly antimalarial treatments. It highlights the challenges of treating malaria in children, who are among the most vulnerable to the disease, and the need for safe, effective, and easy-to-adminis...ter formulations. MMV collaborates with global partners to ensure access to pediatric antimalarial medicines, such as dispersible tablets and rectal treatments, especially in low-resource settings. The page emphasizes the importance of innovation, accessibility, and partnerships in reducing childhood malaria mortality.
more
Este documento del CLAP/SMR (Centro Latinoamericano de Perinatología) aborda las infecciones de transmisión vertical, es decir, aquellas que se transmiten de la madre al niño durante el embarazo, el parto o el período neonatal. Se presenta una tabla detallada con distintos agentes infecciosos (c...omo VIH, sífilis, toxoplasmosis, hepatitis B y C, citomegalovirus, entre otros), describiendo su forma de transmisión, diagnóstico, prevención, tratamiento y seguimiento.
Además, se destacan estrategias sistemáticas de tamizaje materno y neonatal, intervenciones prenatales y postnatales, así como recomendaciones específicas para cada patógeno. El objetivo es reducir los resultados adversos perinatales mediante intervenciones basadas en la evidencia y adaptadas al contexto latinoamericano.
more
The MSF malaria guidelines provide practical, evidence-based recommendations for diagnosing, treating, and preventing malaria, especially in low-resource settings. They cover uncomplicated and severe cases, recommend rapid tests and artemisinin-based therapies, and include special guidance for vulne...rable groups like children and pregnant women.
more
Ce document intitulé « Diagnostic, traitement et prévention du paludisme : directive pour le personnel médical », publié par les Nations Unies en avril 2019, fournit des recommandations pratiques pour le personnel médical travaillant dans des zones à risque de paludisme. Il décrit les signe...s cliniques du paludisme, les méthodes de diagnostic (tests rapides et microscopie), et détaille les traitements recommandés selon l’espèce de Plasmodium et la gravité de l’infection. Il aborde également les cas particuliers, comme les femmes enceintes et les enfants, ainsi que la prévention à travers les moustiquaires, les répulsifs et la chimioprophylaxie. Enfin, il donne des consignes pour les voyageurs de l’ONU, y compris la conduite à tenir en cas de fièvre après un retour de zone endémique.
more
La page du site VIDAL intitulée « Paludisme : traitement – Recommandations » présente les recommandations actuelles pour la prise en charge du paludisme. Elle détaille les différents traitements selon le type de paludisme (P. falciparum ou non), la gravité de l'infection (simple ou sévère...) et le contexte (enfants, femmes enceintes, zones de résistance). Elle aborde également les protocoles de traitement, les médicaments recommandés (comme l'artéméther-luméfantrine ou l'atovaquone-proguanil), ainsi que les précautions à prendre en cas d’automédication ou de voyage en zone endémique.
more
Malaria in pregnancy is a significant health problem in malaria-endemic areas. It not only causes substantial childhood morbidity and mortality but also increases the risks of adverse events for pregnant women and their developing fetuses. Most of the burden in these areas is due to infection with P...lasmodium falciparum. Artemisinin-based combination therapy (ACT) has been recommended as first-line treatment for uncomplicated P. falciparum malaria in all populations, including pregnant women in their second and third trimesters, since 2006. However, for women in their first trimester of pregnancy, WHO recommended as first-line treatment a combination of quinine and clindamycin.
Based on a review of the evidence conducted in 2022, WHO now recommends artemether–lumefantrine, the ACT with the most human safety data available, as the preferred treatment for uncomplicated P. falciparum malaria in the first trimester of pregnancy. This document presents all relevant evidence on the effects and safety in early pregnancy of artemisinins and partner medicines used in ACTs from both studies in experimental animals and observational studies in humans.
more
Government spending on health from domestic sources is an important indicator of a government's commitment to the health of its people, and is essential for the sustainability of health programmes. We aimed to systematically analyse all data sources available for government spending on health in dev...eloping countries; describe trends in public financing of health; and test the extent to which they were related to changes in gross domestic product (GDP), government size, HIV prevalence, debt relief, and development assistance for health (DAH) to governmental and non-governmental sectors.
more
Background
Four methods have previously been used to track aid for reproductive, maternal, newborn, and child health (RMNCH). At a meeting of donors and stakeholders in May, 2018, a single, agreed method was requested to produce accurate, predictable, transparent, and up-to-date estimates that coul...d be used for analyses from both donor and recipient perspectives. Muskoka2 was developed to meet these needs. We describe Muskoka2 and present estimates of levels and trends in aid for RMNCH in 2002–17, with a focus on the latest estimates for 2017.
Methods
Muskoka2 is an automated algorithm that generates disaggregated estimates of aid for reproductive health, maternal and newborn health, and child health at the global, donor, and recipient-country levels. We applied Muskoka2 to the Organisation for Economic Co-operation and Development's Creditor Reporting System (CRS) aid activities database to generate estimates of RMNCH disbursements in 2002–17. The percentage of disbursements that benefit RMNCH was determined using CRS purpose codes for all donors except Gavi, the Vaccine Alliance; the UN Population Fund; and UNICEF; for which fixed percentages of aid were considered to benefit RMNCH. We analysed funding by donor for the 20 largest donors, by recipient-country income group, and by recipient for the 16 countries with the greatest RMNCH need, defined as the countries with the worst levels in 2015 on each of seven health indicators.
Findings
After 3 years of stagnation, reported aid for RMNCH reached $15·9 billion in 2017, the highest amount ever reported. Among donors reporting in both 2016 and 2017, aid increased by 10% ($1·4 billion) to $15·4 billion between 2016 and 2017. Child health received almost half of RMNCH disbursements in 2017 (46%, $7·4 billion), followed by reproductive health (34%, $5·4 billion), and maternal and newborn health (19%, $3·1 billion). The USA ($5·8 billion) and the UK ($1·6 billion) were the largest bilateral donors, disbursing 46% of all RMNCH funding in 2017 (including shares of their core contributions to multilaterals). The Global Fund and Gavi were the largest multilateral donors, disbursing $1·7 billion and $1·5 billion, respectively, for RMNCH from their core budgets. The proportion of aid for RMNCH received by low-income countries increased from 31% in 2002 to 52% in 2017. Nigeria received 7% ($1·1 billion) of all aid for RMNCH in 2017, followed by Ethiopia (6%, $876 million), Kenya (5%, $754 million), and Tanzania (5%, $751 million).
Interpretation
Muskoka2 retains the speed, transparency, and donor buy-in of the G8's previous Muskoka approach and incorporates eight innovations to improve precision. Although aid for RMNCH increased in 2017, low-income and middle-income countries still experience substantial funding gaps and threats to future funding. Maternal and newborn health receives considerably less funding than reproductive health or child health, which is a persistent issue requiring urgent attention.
Funding
Bill & Melinda Gates Foundation; Partnership for Maternal, Newborn & Child Health.
more